RECTAL ADENOCARCINOMA

This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to a standard treatment plan (short-course radiation, chemotherapy, and a targeted therapy) can improve outcomes for people with locally advanced rectal cancer. About 104 adults with a specific type of rectal …

This study tests whether giving extra internal radiation (brachytherapy) to rectal cancer patients who still have some tumor after standard treatment can make the cancer disappear and avoid the need for surgery. About 44 adults will receive three weekly outpatient treatments. The…

This early-phase trial is testing whether people with stage II-III rectal cancer can safely avoid surgery by using chemotherapy followed by active surveillance (close monitoring) instead of immediate surgery. The goal is to preserve the rectum and avoid the need for a permanent c…

This study tests whether people with rectal cancer who have a complete response to initial treatment can safely avoid surgery. About 200 participants will be monitored closely to see how well this non-operative approach works. The goal is to preserve the rectum and maintain good …

This study tests whether giving the immunotherapy drug TSR-042 first, followed by standard chemoradiotherapy and surgery, can shrink or eliminate advanced solid tumors that have a specific genetic feature called mismatch repair deficiency (dMMR). About 212 adults with locally adv…

This study is for people with locally advanced rectal cancer. It tests whether adding the antibiotic metronidazole to standard treatment can lower levels of harmful bacteria in the tumor. About 60 adults will take part. The goal is to see if this approach is safe and can improve …

This early-phase study tests whether MRI-guided adaptive radiation therapy can safely control rectal cancer while allowing patients to keep their rectum. About 22 adults with stage I–III rectal cancer will receive radiation that adjusts in real time based on MRI images. The main …

This early-phase study tests whether a short course of radiation followed by chemotherapy can shrink advanced rectal tumors enough to avoid surgery. About 25 people with stage II or III rectal cancer will receive this treatment. The goal is to preserve the rectum and improve qual…

This study is for people with a certain type of advanced rectal cancer called HER2-positive. Researchers are testing whether adding two targeted drugs, tucatinib and trastuzumab, to standard chemotherapy can shrink tumors more effectively before surgery or radiation. About 37 adu…

This study tests a new treatment for people with advanced colorectal cancer that has a specific gene change called KRAS G12C. The experimental treatment adds two targeted drugs (calderasib and cetuximab) to standard chemotherapy. The goal is to see if this combination helps peopl…

This study tests a new combination of three drugs (trastuzumab-deruxtecan, capecitabine, and bevacizumab) as a first treatment for people with HER-2 positive colorectal cancer that has spread or cannot be removed by surgery. The goal is to see how many patients' tumors shrink or …

This study tests a personalized, stage-based treatment plan for people with rectal cancer that has not spread. The goal is to avoid removing the rectum when possible, using less invasive surgeries like laparoscopy or robotics to reduce physical and emotional side effects. About 2…

This study follows 430 people with rectal cancer (stages I–IV) to see how surgery affects their quality of life. Participants fill out questionnaires about their health and daily activities. The goal is to learn what matters most to patients after treatment, not to test a new dru…

This study follows 100 adults with rectal cancer for up to 2 years after surgery to see how bowel function changes over time. Researchers will compare different treatment plans to find out which ones lead to better bowel control and quality of life. The goal is to help doctors an…

This study looks at whether a simple blood test can help doctors decide if rectal cancer patients can avoid surgery and keep their rectum. Researchers will measure tiny bits of tumor DNA in the blood (ctDNA) before, during, and after standard treatment in 50 adults with stage II …